Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study

BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study

Bristol Myers Squibb (BMS) has reported positive topline results from a phase 3 study of CAR-T therapy Breyanzi as a second-line treatment for relapsed or refractory large B-cell ... The CAR-T therapy also met key secondary endpoints of complete

Latest news

More from news
Approximately 17 fully matching, plus 96 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • In the precision medicine era, the line between products and services is blurred

    In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to ... However, due to its novelty, it was difficult to access patients who have

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • The balancing act that’s keeping pharma and biotech market access on its toes

    CAR-T cell therapy costs  close to $500, 000 per patient in the US, and  300, 000 in Europe. ... Zolgensma, gene therapy for the treatment of spinal muscular atrophy, is (at the time of writing) the  most expensive drug in the world at $2.1m.

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...